



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, December 4<sup>th</sup>, 2025  
1:05 PM - 4:45 PM  
Via Zoom webinar

### MEETING MINUTES

---

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333**

**Members Present:** Stacy Ramirez, PharmD; Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD;

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells; Jennifer Bowen; Michael Yu, DC; Kyle Hamilton

**Audience:** Leland Turner\*, Chiesi; Keith Liully\*, Abeona; Andrea Hawkinson\*, Recordati; Janelle Raymond\*, IntraBio; Amber Svardal\*, Precigen; Andrew Albanese, OHSU; Krystal Ngo\*, Arcutis Biotherapeutics; Valerie Ng\*, LEO Pharma; Joe Cirrincione\*, Incyte; Shawn Akey, Concis Labs; Ron Abraham; Erin Estock, Arcutis; Gary Parenteau, Dexcom; Miranda Tyzenman, Artia Soln; Oyinda; Rosalie Elliott, Umpqua; William White, Abeona; Michael Foster, Ultradent; Lee Stout, Chiesi; Erin Nowak, AbbVie; Jessica Garrison, Gainwell Tech; Tammi Ocumpaugh, Otsuka; Chris Ferrin, IHN; Michele Pannell, Alkermes; Lisa Pulver; Brett Freund; Vivian Ton, UHA; Georgette Dzwilewski; Gloria Zepeda, AllCare; Lewis Backus, OHA; Daria Meleshkina, EOCCO; Jill Carol, BMS; Mark Kantor, AllCare; Courtney Ho; Trung Nguyen; Kim Michelet; Beth Giblin

**(\*) Provided verbal testimony**

---

### I. CALL TO ORDER

- A. Roll Call & Introductions
  - Meeting called to order at approx. 1:05 p.m., introductions by Committee and Staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and October Minutes presented by Roger Citron, RPh
  - ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- D. Department Update provided by Trevor Douglass, DC
- E. Mental Health Clinical Advisory Group Update presented by Andrew Gibler, PharmD



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

---

## II. CONSENT AGENDA TOPICS

- A. **Quarterly Utilization Report**
- B. **Oncology Prior Authorization (PA) Updates**

**Recommendation:**

- Add: Inluriyo™ (imlunestrant) and Keytruda Qlex™ (pembrolizumab + berahyaluronidase alfa-pmph) to Table 1 in the Oncology Agents PA criteria

- C. **Orphan Drug Policy Updates**

**Recommendation:**

- Update Table 1 in the Orphan Drugs PA criteria to: support medically appropriate use of Strengiq® (asfotase alfa); Vimizim® (elosulfase alfa); Naglazyme® (galsulfase); Elaprase® (Idursulfase) and Mepsevii™ (vestronidase alfa-vjbk) based on their FDA-approved label; remove drugs for which specific PA criteria are proposed; and update to clarify the high-cost drugs that will be carved out and covered by fee-for-service (FFS).

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## III. DUR ACTIVITIES

- A. **ProDUR Report:** Lan Starkweather, PharmD
- B. **RetroDUR Report:** Dave Engen, PharmD
- C. **Oregon State Drug Review:** Kathy Sentena, PharmD
  - 1. **The Mental Health Clinical Advisory Group**
  - 2. **Pharmacotherapeutic Options for Treating Adolescents with Opioid Use Disorder**
  - 3. **Medication Safety Update**

---

## IV. NEW BUSINESS

- A. **Antifungals Class Update:** Kathy Sentena, PharmD

**Recommendations:**

- Make no changes to the PDL based on review of the clinical evidence
- Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

- B. **Epidermolysis Bullosa New Drug Evaluations (NDEs):** Sarah Servid, PharmD

**Recommendations:**

- Implement proposed PA criteria for high-cost treatments for epidermolysis bullosa including birch triterpenes, beremagene geperpavec and prademagene zamikeracel
- Review costs in executive session

**Public Comment:** Leland Turner, Chiesi; Keith Dilly, Abeona

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

- C. **Carbaglu® (carglumic acid) NDE:** Deanna Moretz, PharmD



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

**Recommendations:**

- Make one caglumic acid product preferred on the PDL
- Implement proposed PA criteria to ensure appropriate use
- Evaluate comparative costs in executive session

**Public Comment:** Andrea Hawkinson, Recordati

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**D. Niemann-Pick Type C NDEs:** Sara Fletcher, PharmD

**Recommendations:**

- Make arimoclomol and levacetylleucine non-preferred on the PDL
- Implement proposed PA for high-cost treatments for Niemann-Pick disease type C
- Implement separate miglustat PA for 100 mg formulation with corresponding updates to PA criteria for Pompe Disease and Gaucher disease
- Evaluate comparative costs in executive session

**Public Comment:** Janelle Raymond, IntraBio

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**E. Papzimeos™ (zopapogene imadenovec-drba) NDE:** Kathy Sentena, PharmD

**Recommendations:**

- Designate zopapogene imadenovec-drba as non-preferred on the PDL
- Implement proposed PA criteria to allow coverage for adult patients when other recurrent respiratory papillomatosis treatments have failed

**Public Comment:** Amber Svardal, Precigen; Andrew Albanese, OHSU

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**F. Sohonos® (palovarotene) NDE:** Dave Engen, PharmD

**Recommendations:**

- Designate palovarotene as non-preferred on the PDL
- Implement proposed PA criteria for palovarotene to ensure safe and appropriate use for children and adults with fibrodysplasia ossificans progressiva

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**G. Topicals for Inflammatory Skin Disease Class Update with NDE:** Deanna Moretz, PharmD

**Recommendations:**

- Revise PA criteria for the "Topical Agents for Inflammatory Skin Conditions" to include expanded indications for ruxolitinib cream, ruxolitinib foam, roflumilast cream, sirolimus gel, and tapinarof cream
- Maintain delgocitinib cream and make sirolimus topical gel non-preferred on the PDL
- Evaluate comparative costs in executive session

**Public Comment:** Krystal Ngo, Arcutis Biotherapeutics; Valerie Ng, LEO Pharma; Joe Cirrincione, Incyte

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

---

## V. EXECUTIVE SESSION

**Members Present:** Stacy Ramirez, PharmD; Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Jessica Garrison, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

---

## VI. RECONVENE for PUBLIC RECOMMENDATIONS

### A. Antifungals Class

**Recommendations:** Make terbinafine tablets; miconazole (solution & powder); ciclopirox (gel, solution & cream); ketoconazole (shampoo & cream); clotrimazole cream; clotrimazole-betamethasone cream; nystatin-triamcinolone cream; and miconazole 3-day suppository kit preferred. Make all other products non-preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

### B. Epidermolysis Bullosa

**Recommendations:** Make Zevaskyn (prademagene zamikeracel), Filsuvez (birch triterpenes) and Vyjuvek (prademagene geperpavec) non-preferred and continue to explore SR offers and VBAs

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

### C. Carbaglu® (carglumic acid)

**Recommendations:** Make Carbaglu dispersible tablets preferred and generic carglumic acid non-preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

### D. Niemann-Pick Type C

**Recommendations:** Make brand Zavesca tablets preferred

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

### E. Topicals for Inflammatory Skin Disease

**Recommendations:** Make no changes to the PDL

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## VII. ADJOURN